Respiratory Conditions

December 03, 2021

The composition of the microbiota of the airways of people with chronic obstructive pulmonary disorder explains varying degrees of inflammation, according to a review article published recently in the Annals of Medicine.

December 02, 2021

University of Buffalo researchers found that men with low incomes were at greater risk of hospital readmission.

November 24, 2021

The traditional dividing line between transmission by droplets and smaller aerosols is incorrect, say the authors of a Annals of Internal Medicine review paper, and infection control measures need to reflect the new understanding that respiratory viruses spread in respiratory particles of all sizes and perhaps mainly in aerosols.

November 10, 2021

Long-term exposure to particulate matter ≤2.5 μm (PM2.5) is associated with increased admission to the hospital for COVID-19.

October 31, 2021

An understanding of hemoglobin levels in patients with COPD could help guide disease management.

October 25, 2021

Recently approved for children 6 to 11 years, Dupixent reduces severe asthma attacks and improves lung function.

September 24, 2021

In a study conducted by JAMA, results were recently released sharing children with active asthma had reduced symptom days, but not significantly, in the use of a school-wide integrated pest management program or a high-efficiency particulate air filter purifier in recorded 2-week time periods.

September 23, 2021

Efforts are underway to accelerate the development of a novel therapy for excessive airway mucus and inflammation treatment for patients with chronic obstructive pulmonary disease and non-cystic fibrosis bronchiectasis.

September 23, 2021

Three experts say that pulmonary rehabilitation programs don’t necessarily result in improved lung function but are associated with improved physical and other sorts of functioning. Less than 5% of those who might benefit from pulmonary rehabilitation services received them.

September 17, 2021

Tezepelumab, which is being currently reviewed by the FDA, provides small improvements in daily symptoms and quality of life but is only modestly cost-effectiveness at the anticipated price, according to the cost-effectiveness group's calculations.